Pasithea Therapeutics KTTA
NASDAQ KTTA
$0.48 -0.01 (-2.04%)
At close: Oct 2, 2026 · 4:00 PM EDT

Pasithea Therapeutics (KTTA) Return on Sales [ROS] (2022)

Updated

Pasithea Therapeutics (KTTA) posted Return on Sales [ROS] of -1679.52% for Q4 2022, up 84.24 percentage points from the prior quarter.

Analysis

Pasithea Therapeutics (KTTA) Return on Sales [ROS] (2022) Analysis & Trends

For FY2022, Pasithea Therapeutics' Return on Sales [ROS] came in at -2587.35%, up 27338.38 percentage points from FY2021.

  • In prior years, Pasithea Therapeutics' Return on Sales [ROS] was -29925.73% in FY2021.
  • According to Business Quant data, Return on Sales [ROS] for the three prior quarters was -1763.76% (Q3 2022), -19229.50% (Q2 2022) and -17605.34% (Q1 2022).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 28.21%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 37.86%
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -3.52%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 32.97%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 20.57%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 34.95%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -133.21%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 28.37%
10 Pasithea Therapeutics 16.04 Mn 16.04 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 -1,679.52%
Sep 30, 2022 -1,763.76%
Jun 30, 2022 -19,229.50%
Mar 31, 2022 -17,605.34%
API Access

Pasithea Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=KTTA&period=max&api_key=YOUR_API_KEY